Prof. Sarne has published several studies on neuroprotection induced by ultra-low doses of THC in cognitive deficits resulting from various insults, including hypoxia, epileptic seizures, neurotoxicity and brain inflammation.
The advantage of using ultra low doses is the lack of side effect (either mental or physical) and the avoidance of desensitization/ habituation that may require the elevation of applied doses, especially in the case of repeated applications or chronic treatment remove: and the ability to use for a long-term treatment (repeated doses or chronic application). The lipophylic cannabinoid drugs and their metabolites are only slowly washed out and tend to accumulate in the body.
The conventional doses of THC (as well as of other cannabinoid drugs) that are required to induce the known cannabinoid effects in mice are 2-20 mg/kg. Prof Sarne We have has shown in his studies that X1000 times a lower dose (0.002 mg/kg) provide long-lasting beneficial effect .
The wide therapeutic window enable us to suggest a wide range of effective doses (10- 400ug) in humans with no cannabinoid side effects and without undergoing desensitization remove: / habituation.
Project ID : 10-2014-850
Ultra-low doses of THC for the treatment of cognitive deficits
Prof. Sarne has published several studies on neuroprotection induced by ultra-low doses of THC against cognitive damage that results from various insults, including hypoxia, epileptic seizures, neurotoxicity and brain inflammation (see attached two articles).
The advantage of using ultra low doses is the lack of side effects (either mental or physical) and the avoidance of desensitization/ habituation that may require the elevation of applied doses, especially in the case of repeated applications or chronic treatment.
The conventional doses of THC (as well as of other cannabinoid drugs) that are required to induce the known cannabinoid effects in mice are 1-20 mg/kg. We have shown that X1000 lower dose (0.002 mg/kg) provide long-lasting beneficial effects.
The wide therapeutic window enables us to suggest a wide range of effective doses (10- 400ug) in humans with no cannabinoid side effects and without undergoing desensitization.
We are seeking a collaboration with a pharma company aimed at demonstrating clinical proof-of-concept. Since THC at high doses is already approved for medical treatments in humans, clinical studies with the ultra-low doses are expected to be straight forward
Project manager
Elisha Natan
Director BD
Project researchers
Yosef Sarne
T.A.U Tel Aviv University, Medicine-Sackler Faculty
Physiology and Pharmacology
Ramot is Tel Aviv University's (TAU) technology transfer company and its liaison to industry, bringing promising scientific discoveries made at the university to industry's attention. The company provides the legal and commercial frameworks for inventions made by TAU faculty, students and researchers, protecting discoveries with patents and working jointly with industry to bring scientific innovations to the market.
Create your free account to connect with RAMOT at Tel Aviv University Ltd. and thousands of other innovative organizations and professionals worldwide
Send a request for information
to RAMOT at Tel Aviv University Ltd.
Technology Offers on Innoget are directly posted
and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.
Need help requesting additional information or have questions regarding this Technology Offer?
Contact Innoget support
